Cleared Traditional

K181594 - Spectralis HRA+OCT and variants with OCT Angiography Module (FDA 510(k) Clearance)

Sep 2018
Decision
87d
Days
Class 2
Risk

K181594 is an FDA 510(k) clearance for the Spectralis HRA+OCT and variants with OCT Angiography Module. This device is classified as a Tomography, Optical Coherence (Class II - Special Controls, product code OBO).

Submitted by Heidelberg Engineering GmbH (Heidelberg, DE). The FDA issued a Cleared decision on September 13, 2018, 87 days after receiving the submission on June 18, 2018.

This device falls under the Ophthalmic FDA review panel. Regulated under 21 CFR 886.1570. Viewing, Imaging, Measurement, And Analysis Of Ocular Structures. Diagnostic Device To Aid In The Detection And Management Of Various Ocular Diseases..

Submission Details

510(k) Number K181594 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 18, 2018
Decision Date September 13, 2018
Days to Decision 87 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary Summary PDF

Device Classification

Product Code OBO - Tomography, Optical Coherence
Device Class Class II - Special Controls
CFR Regulation 21 CFR 886.1570
Definition Viewing, Imaging, Measurement, And Analysis Of Ocular Structures. Diagnostic Device To Aid In The Detection And Management Of Various Ocular Diseases.